DIMACS Subgroup on Adverse Event/Disease Reporting, Surveillance, and Analysis
DIMACS Working Group on Adverse Event/Disease Reporting, Surveillance, and Analysis II
Wednesday, October 16, 2002
Session I: Scope and purpose of disease and adverse event reporting and analysis Moderator: Henry Rolka 8:45-9:00 Welcome and Introductory Comments Fred Roberts, DIMACS 9:00-9:25 Overview of Uses for Public Health Surveillance Dan Sosin, CDC 9:25-9:50 Overview of the Information Systems Currently Available to Public Health Researchers David Walker, CDC 9:50-10:15 An Introduction to Multiple Systems Estimation for Estimating a Count of Adverse Events Jana Asher, CMU 10:15-10:30 break 10:30-10:55 Periodic Reporting of Post-licensure Safety Data to FDA by Pharmaceutical Firms: Relation to "Datamining"? Miles Braun, FDA 10:55-11:20 Some Problems and Challenges with Our Current Reporting Systems, Data Sources and Approaches: Lessons from the HIV/AIDS Epidemic Meade Morgan, CDC 11:20-11:45 Syndromic Surveillance- The New York City Experience, with some Lessons from the National Syndromic Surveillance Conference Farzad Mostashari, NYC Dept. of Health 11:45-12:00 Floor Discussion and Group Assignment 12:00-1:00 Lunch 1:00-3:00 Breakout Session Break into several (~5) groups. Each group has a moderator. Each group is to discuss a particular question: Concerning disease and adverse event reporting and surveillance, what are the major issues that need to be addressed? Groups should be cognizant of peace-time needs as well as deliberate threats. What should be the role(s) of standards (data model, vocabulary, message format, etc) in AE and Disease Surveillance? What areas of standardization need to be raised in priority? What areas are under addressed? How should public health informatics interact more with SDO's? What improvements could be made in the national (international?) capability of developing new and better analytic tools (software) and methods for analysis of AE, etc.? Develop a list of research priorities and recommendations in the area of detection and analysis of AE, etc. Related issues include: - the role of government - the role of higher education - software development - privacy 3:00-4:30 Panel Session: Informal presentations by group moderators. Open discussion. 4:30-6:00 Wine and CheeseThursday, October 17, 2002
Session II: Data sources and issues Moderator: Don Hoover 8:45-9:10 The "Homeland Security - Public Health" Challenge: Connecting and Integrating the Sources and the Players with the Applications Luis Kun 9:10-9:35 Overview: use of non-reported/administrative data for surveillance (ER data, pharmacy data, 911 call data, Harvard pilgrim, etc.) Latanya Sweeney, Carnegie-Mellon University 9:35-10:00 Pharmacoepidemiology - Goals and Methods Sean Hennessy, University of Pennsylvania 10:00-10:15 break 10:15-10:40 FDA's Adverse Event Reporting System and the Use of quantitative Methods for Screening Robert O'Neill, FDA 10:40-11:05 Surveillance methods for birth defects and developmental disabilities-understanding the limitations of different approaches Coleen Boyle, CDC 11:05-11:30 NEDSS in detail Joseph Reid, CDC 11:30-12:10 Lab data? Clinical data? Over-the-counter data? Gil Delgado, Emergint 12:10-1:10 Lunch 1:10-1:50 Using Electronic Healthcare Reimbursement Claims to Detect Local, Regional, and National Infectious Disease Outbreaks Thomas Balzer, Quintiles/Verispan 1:50- 2:45 Groups reconvene to create recommendations 2:45-3:00 Break 3:00-3:20 The Bioterrorism Preparedness and Response Program, Early Aberration Reporting System (EARS) Lori Hutwagner, CDC 3:20-3:40 Bayesian Methods for Monitoring Public Health Surveillance Data Owen Devine, CDC 3:40-5:00 Group leaders present group recommendations Also discussion of: "Evaluation of surveillance systems - how can the working group play a role?" lead by Rolka and MadiganFriday, October 18, 2002
Session III: Analytics Moderator: David Madigan Introductory Remarks: Susan Ellenberg, FDA 9:00-9:20 A Tree-Based Scan Statistic for Database Disease Surveillance Martin Kulldorff, University of Connecticut 9:20-9:40 Methods for Capture-Recapture Estimates of the Number of Pertussis Cases in New York State When Individuals Are Not Uniquely Identifiable Phil Smith, CDC 9:40-10:00 Data mining methods: Applications, problems and opportunities in the public sector John Stultz, SAS Institute 10:00-10:20 Datamining in the Vaccine Adverse Event Reporting System (VAERS) to Enhance Vaccine Safety Monitoring at the Food and Drug Administration (FDA) Robert Ball, FDA 10:20-10:35 Break 10:35-12:00 Open Session Introductory comments by Steve Fienberg How do we stitch this into a coherent whole? Does the Working Group serve a useful role? What format should future activities adopt? How do we develop and manage a viable business implementation and usage coordination plan for this?
Previous: List of Participants
Working Group Index
DIMACS Homepage